Nederlands (Nederland)
Online toolkit
Together for responsible advicePhasing out responsibly is done together
Prescribing and phasing out antidepressants is and remains personalised medicine. After all, every patient reacts differently. It is important that pharmacists and treating physicians have the possible tools to guide this process properly.
Phase out schedules (download PDF)
Work together with the patient to develop a clear and understandable phase out plan to help guide them through the process.
Risk factors for withdrawal symptoms
Patients who stop an SSRI or SNRI abruptly or within days are at risk of experiencing withdrawal symptoms (20-78%).Therefore, discuss the risk factors with the patient beforehand and then decide together on the pace of tapering and the appropriate dosage steps.
Reimbursement
Medication for antidepressant tapering according to Table 3 of the multidisciplinary document will be reimbursed under the terms of the claim: Tapering in accordance with the multidisciplinary document (Table 3).Do you have specific questions about reimbursement? If so, please contact our Innovation Department using the button below:
Multidisciplinary documentÂ
"Phasing out SSRI & SNRI"
The multidisciplinary document "Phasing out SSRI & SNRI" is a good guide to phasing out antidepressants gradually and responsibly, but together.The recommendations from this multidisciplinary document4 are set out below:
- Abruptly stopping a SSRI or SNRI is not recommended
- Information and guidance before and during the phasing-out period is crucial
- Work together to determine the pace and steps of phasing out process
FTO material available
FTO work materials are available through "Instituut Verantwoord Medicijngebruik" for use in pharmacies and general practices.References:
1 ZonMw, OPERA: grote trial brengt veilig afbouwen antidepressiva dichterbij, nov 2018
2Â nhg-standaard-depressie-tweede-herziening.
3 In de Praktische toelichting op multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’Â
4 Een selectie van de aanbevelingen uit het Multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’
Let us know how we can better meet your needs and those of your patients.
Phasing out responsibly is done together
Prescribing and phasing out antidepressants is and remains personalised medicine. After all, every patient
reacts differently. It is important that pharmacists and treating physicians have the possible tools to guide this process properly.Multidisciplinary documentÂ
"Phasing out SSRI & SNRI"
The multidisciplinary document "Phasing out SSRI & SNRI" is a good guide to phasing out antidepressants gradually and responsibly, but together.The recommendations from this multidisciplinary document4 are set out below:
- Abruptly stopping a SSRI or SNRI is not recommended
- Information and guidance before and during the phasing-out period is crucial
- Work together to determine the pace and steps of phasing out process
Phase out schedules (download PDF)
Work together with the patient to develop a clear and understandable phase out plan to help guide them through the process.
Fagron FTO material available
Fagron FTO materials are available for use in pharmacies and general practices, as an addition to the IVM materials.IVM FTO material available
FTO work materials are available through "Instituut Verantwoord Medicijngebruik" for use in pharmacies and general practices.Risk factors for withdrawal symptoms
Patients who stop an SSRI or SNRI abruptly or within days are at risk of experiencing withdrawal symptoms (20-78%).Therefore, discuss the risk factors with the patient beforehand and then decide together on the pace of tapering and the appropriate dosage steps.
Reimbursement
Medication for antidepressant tapering according to Table 3 of the multidisciplinary document will be reimbursed under the terms of the claim: Tapering in accordance with the multidisciplinary document (Table 3).Do you have specific questions about reimbursement? If so, please contact our Innovation Department using the button below:
References:
1 ZonMw, OPERA: grote trial brengt veilig afbouwen antidepressiva dichterbij, nov 2018
2Â nhg-standaard-depressie-tweede-herziening.
3 In de Praktische toelichting op multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’Â
4 Een selectie van de aanbevelingen uit het Multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’
1 ZonMw, OPERA: grote trial brengt veilig afbouwen antidepressiva dichterbij, nov 2018
2Â nhg-standaard-depressie-tweede-herziening.
3 In de Praktische toelichting op multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’Â
4 Een selectie van de aanbevelingen uit het Multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’